Related Experiment Video
Updated: Jul 2, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Reporting macrolide-resistant Mycoplasma pneumoniae: a diagnostic obligation?
1Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract:
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is increasingly detected worldwide, with increasing prevalence even in the United States. Detection of resistance within M. pneumoniae has meaningful clinical and stewardship implications. Resistance is most commonly mediated by point mutations within 23S rRNA and can be reliably identified by molecular assays, not just on isolates butalso on primary respiratory samples like swabs. Multiple studies associate macrolide resistance with prolonged fever, delayed clinical response, increased healthcare utilization, and greater antibiotic exposure due to delay or treatment failure. The detection of resistance can meaningfully influence the clinical course and overall patient outcomes. Though clinical disease is not any more severe in infections with resistant isolates, failure to report may perpetuate unnecessary macrolide use, leading to delay in transition to effective second-line agents (tetracyclines or fluoroquinolones when appropriate), and contribute to selective pressure. Beyond individual patient care, routine reporting provides valuable local epidemiologic data to inform empiric therapy, support outbreak recognition, and guide antimicrobial stewardship initiatives. Even so, a significant clinical gap remains as most commercially available diagnostic assays do not routinely detect or report resistance markers in Mycoplasma pneumoniae. Moreover, even among assays designed to detect resistance, performance can vary considerably with reduced sensitivity for organism detection and incomplete identification of key 23S rRNA mutations reported in comparative evaluations, as reported by Hénin N, Silvant A, Gardette M, Balcon C, Guiraud J, Bébéar C, Pereyre S, J Clin Microbiol 64: e0149125, 2026, https://doi.org/10.1128/jcm.01491-25. Focused efforts are, therefore, needed to close existing diagnostic and reporting gaps to ensure resistance detection is more consistently integrated into routine clinical practice.
Insights
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is rising globally. Detecting this resistance impacts treatment, improving patient outcomes and guiding antibiotic stewardship by enabling timely use of alternative therapies.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a growing global health concern, with increasing detection in the United States.
- Resistance in M. pneumoniae is primarily caused by 23S rRNA gene mutations, detectable via molecular assays on respiratory samples.
- Macrolide resistance is linked to prolonged illness, increased healthcare use, and delayed effective treatment.
Purpose of the Study:
- To highlight the clinical and public health implications of MRMP.
- To emphasize the need for improved diagnostic and reporting of macrolide resistance in M. pneumoniae.
- To address the gap in current commercial diagnostic assays regarding resistance detection.
Main Methods:
- Review of existing literature on MRMP prevalence, mechanisms, and clinical impact.
- Analysis of the role of molecular assays in detecting 23S rRNA mutations.
- Evaluation of the current limitations of commercially available diagnostic assays.
Main Results:
- Macrolide resistance in M. pneumoniae is associated with poorer clinical outcomes and increased antibiotic exposure.
- Molecular assays can reliably detect resistance markers in respiratory samples.
- Many commercial diagnostic tests fail to detect or report MRMP, contributing to diagnostic and stewardship gaps.
Conclusions:
- Accurate and timely detection of MRMP is crucial for effective patient management and antimicrobial stewardship.
- Enhanced diagnostic capabilities and routine reporting of resistance markers are needed.
- Closing the existing gaps will improve empiric therapy, outbreak recognition, and overall patient care.
Related Concept Videos
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Pneumonia III: Complications and Assessment